NEW YORK, J (GLOBE NEWSWIRE) - Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) and Callisto Pharmaceuticals, Inc. (OTCBB:CLSP)
A group of former officers and directors of Synergy Pharmaceuticals Inc. is resisting a litigation trust's efforts to acquire documents for
NEW YORK-Synergy Pharmaceuticals, Inc. (OTC BB: SGYP) (the.
NASDAQ:SGYP Shareholder Notice: Deadline on Ap in Lawsuit Against Synergy Pharmaceuticals Inc San Diego, CA - (SBWIRE) - - The Shareholders Foundation announces that a deadline is coming up on Ap in the lawsuit filed for certain investors of Synergy Pharmaceuticals Inc (NASDAQ: SGYP) over alleged securities laws violations by Synergy Pharmaceuticals Inc .
Bausch Health Companies Inc Synergy Pharmaceuticals is engaged in the development and commercialisation of new treatment options for patients
NEW YORK, Ma /PRNewswire/ - Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the Company or Synergy ), a biopharmaceutical company focused on the development and commercialization of
Bausch Health (BHC) Confirms 'Stalking Horse' Agreement to Acquire Substantially All Assets of Synergy Pharmaceuticals (SGYP) Synergy Pharmaceuticals Inc
After more than a decade of development, US-based Synergy Pharmaceuticals Inc. (Synergy) received marketing approval from the US Federal
On, Synergy Pharmaceuticals Inc. went out of business on completion of liquidation under chapter 11 bankruptcy filing. Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders.
Comments